<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04824872</url>
  </required_header>
  <id_info>
    <org_study_id>ZP4207-20123</org_study_id>
    <nct_id>NCT04824872</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Dasiglucagon for Treatment of Post-bariatric Hypoglycemia in Roux-en-Y Gastric Bypass (RYGB) Operated Adults</brief_title>
  <official_title>A Double-Blind, Placebo-Controlled, Cross-over Trial, Evaluating Efficacy and Safety of Dasiglucagon for Treatment of Post-bariatric Hypoglycemia in Roux-en-Y Gastric Bypass (RYGB) Operated Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zealand Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zealand Pharma</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the trial is to assess the effect of single subcutaneous doses of&#xD;
      dasiglucagon versus placebo on post-prandial plasma glucose nadir following a Mixed Meal Test&#xD;
      in Roux-en-Y Gastric Bypass (RYGB) subjects&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2022</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Nadir plasma glucose concentration</measure>
    <time_frame>From trial drug administration to 240 minutes after initiation of Mixed Meal Test</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent time spent in hypoglycemia</measure>
    <time_frame>From trial drug administration to 240 minutes after initiation of Mixed Meal Test</time_frame>
    <description>Defined as time with a plasma glucose value of 70 mg/dL (3.9 mmol/L) or less</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent time spent in clinical significant hypoglycemia</measure>
    <time_frame>From trial drug administration to 240 minutes after initiation of Mixed Meal Test</time_frame>
    <description>Defined as time with a plasma glucose value of 54 mg/dL (3.0 mmol/L) or less</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent time spent in target range</measure>
    <time_frame>From trial drug administration to 240 minutes after initiation of Mixed Meal Test</time_frame>
    <description>Defined as time with a plasma glucose value of 70-180 mg/dL (3.9-10.0 mmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent time spent in hyperglycemia</measure>
    <time_frame>From trial drug administration to 240 minutes after initiation of Mixed Meal Test</time_frame>
    <description>Defined as time with a plasma glucose value &gt;180 mg/dL (&gt;10 mmol/l)</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Hypoglycemia</condition>
  <condition>Glucose Metabolism Disorders</condition>
  <arm_group>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dasiglucagon high dose, followed by placebo, followed by dasiglucagon low dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dasiglucagn low dose, followed by dasiglucagon high dose, followed by placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo, followed by dasiglucagon low dose, followed by dasiglucagon high dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dasiglucagon high dose, followed by dasiglucagon low dose, followed by placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo, followed by dasiglucagon high dose, followed by dasiglucagn low dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dasiglucagon low dose, followed by placebo, followed by dasiglucagon high dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dasiglucagon</intervention_name>
    <description>dasiglucagon SC, low dose</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_label>Sequence 4</arm_group_label>
    <arm_group_label>Sequence 5</arm_group_label>
    <arm_group_label>Sequence 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dasiglucagon</intervention_name>
    <description>dasiglucagon SC, high dose</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_label>Sequence 4</arm_group_label>
    <arm_group_label>Sequence 5</arm_group_label>
    <arm_group_label>Sequence 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo for dasiglucagon</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_label>Sequence 4</arm_group_label>
    <arm_group_label>Sequence 5</arm_group_label>
    <arm_group_label>Sequence 6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Previously undergone Roux-en-Y gastric bypass (RYGB) surgery at least 6 months prior&#xD;
             to screening&#xD;
&#xD;
          -  Previous diagnosis of post-bariatric hypoglycemia (PBH), requiring intake of oral&#xD;
             carbohydrates.&#xD;
&#xD;
          -  Body mass index (BMI) ≤ 40 kg/m2&#xD;
&#xD;
          -  Fasting plasma glucose between 72-106 mg/dL (4.0-6.0 mmol/l)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of hypersensitivity reactions to glucagon or dasiglucagon or any of the&#xD;
             excipients&#xD;
&#xD;
          -  History of insulinoma, pheochromocytoma, MEN 2A, MEN 2B, neurofibromatosis, or von&#xD;
             Hippel-Lindau disease.&#xD;
&#xD;
          -  Estimated Glomerular Filtration Rate (eGFR) &lt; 30 mL/min/1.73 m2 or end-stage renal&#xD;
             disease at screening&#xD;
&#xD;
          -  Hepatic disease, including serum alanine aminotransferase or aspartate&#xD;
             aminotransferase ≥ 2.5 times the upper limit of normal (ULN)&#xD;
&#xD;
          -  Active malignancy, except for basal or squamous cell skin cancers&#xD;
&#xD;
          -  History of a cerebrovascular accident within 6 months prior to screening&#xD;
&#xD;
          -  History of myocardial infarction, unstable angina, or revascularization within 6&#xD;
             months prior to screening.&#xD;
&#xD;
          -  Congestive heart failure, New York Heart Association Class III or IV&#xD;
&#xD;
          -  Concurrent administration of β-blocker therapy&#xD;
&#xD;
          -  Clinically significant ECG abnormalities at screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Benedikte Bandak, MSc</last_name>
    <phone>+4550603766</phone>
    <email>bba@zealandpharma.com</email>
  </overall_contact>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 29, 2021</study_first_submitted>
  <study_first_submitted_qc>March 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2021</study_first_posted>
  <last_update_submitted>March 29, 2021</last_update_submitted>
  <last_update_submitted_qc>March 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypoglycemia</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
    <mesh_term>Glucose Metabolism Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

